Q&A roundtable discussions are conducted by members of the community to provide opportunities for a small group discussion with subject matter experts.
There are 8 seats at the table for the 90-minute discussion.
A few days prior, we will send out "Confirmation Required" emails to registrants. You must email back to confirm your spot or we will have to release your ticket.
If you are an early stage startup or a researcher with the newest technology, join Cecilia Zapata-Harms of Elev8Bio to discuss startup strategic development. Cecilia can help identify product market fit, target audience and funding from seed to expansion.
Cecilia Zapata-Harms, MS, MHA has held leadership positions in strategy, joint venture startup and program administration. Her career spans more than 30+ years in life science/biotechnology and healthcare industry. Cecilia started her tenure as a strategic planning expert at Fred Hutchinson Cancer Research in the early 1990s. She then became the Program Administrator for the Molecular Pharmacology, Clinical Research Division under the leadership of Dr. Lee Hartwell and Dr. Stephen Friend. The Seattle Project, as it was known in 1994, landed Cecilia as Project Officer for the National Cancer Institute as part of the contract agreement with the Seattle Project.
Cecilia was part of the original team that founded Rosetta Inpharmatics which eventually became a Merck division. In 1998, the Seattle Cancer Care Alliance (SCCA) was formed and Cecilia’s skills as a project manager and strategic planner were recruited to assist with the relocation of clinical staff and programs to its new facility. Cecilia held the position of Director of Strategic Development for the SCCA for two years and eventually became the Director of Affiliate Network and Strategic Outreach, holding that role for 13 years.
In the summer of 2017, Cecilia returned to her life science and biotechnology roots as Chief Executive Officer for Elev8Bio; a company that provides life science/biotech startups the infrastructure to support overall business growth from taking scientific innovation as a startup, investment raise and ongoing management.